Cargando…
Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial
Autores principales: | Wu, Jashin J., Spelman, Lynda, Tan, Jerry L., Etoh, Takafumi, Zhang, Haixin, Shumel, Brad, Rossi, Ana B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019003/ https://www.ncbi.nlm.nih.gov/pubmed/33511576 http://dx.doi.org/10.1007/s13555-021-00487-y |
Ejemplares similares
-
Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)
por: Wollenberg, A., et al.
Publicado: (2019) -
The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis
por: Kamal, Mohamed A., et al.
Publicado: (2021) -
Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis
por: Yosipovitch, Gil, et al.
Publicado: (2021) -
Atopic Dermatitis Treated Safely with Dupilumab during Pregnancy: A Case Report and Review of the Literature
por: Lobo, Yolanka, et al.
Publicado: (2021) -
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study
por: Kimball, Alexa B., et al.
Publicado: (2023)